Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Aripiprazole recalled?

Yes — there is an active recall. 7 ongoing FDA recalls mention Aripiprazole (29 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Aripiprazole. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Aripiprazole recalls on record

none so far in 2026; 29 on record, newest first
Class II · Moderate risk

ARIPiprazole Tablet

Labeling:Label Mixup; ARIPiprazole, Tablet, 15 mg may be potentially mislabeled as ATOMOXETINE HCL, Capsule, 40 mg, NDC 00002322930, Pedigree: AD21790_82, EXP: 5/1/2014; PRAMIPEXOLE DI-HCL, Tablet, 0.125 mg, NDC 13668009190, Pedigree: AD25264_10, EXP: 5/3/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-640-2014
Class II · Moderate risk

ARIPiprazole Tablet

Labeling:Label Mixup; ARIPiprazole Tablet, 2 mg may be potentially mislabeled as tiZANidine HCl, Tablet, 2 mg, NDC 55111017915, Pedigree: AD21790_40, EXP: 5/1/2014; ATOMOXETINE HCL, Capsule, 80 mg, NDC 00002325030, Pedigree: AD30140_19, EXP: 5/7/2014; OLANZapine, Tablet, 7.5 mg, NDC 55111016530, Pedigree: AD46265_46, EXP: 5/15/2014; REPAGLINIDE, Tablet, 2 mg, NDC 00169008481, Pedigree: AD464

Terminated Labeling / mix-up Aidapak Services, LLC D-639-2014
Class II · Moderate risk

ABILIFY (aripiprazole)

CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

Terminated cGMP deviation Bristol Myers Squibb Manufacturing Company NDC 59148-011-35 D-181-2013